Indeed, as described in Table 3, HER-3 expression resulted to be a significant prognostic parameter influencing survival of CRC patients (HR = 3.3: 95% CI, 1.3–8.3; p = 0.011) representing a significant and strong risk factor for death in CRC patients developing MM liver metastases (HR = 64.9; 95% CI, 4.7–886.6; p = 0.002). This evidence concerns the gene ERBB3 and Miyoshi myopathy.